Case Studies

Renal Health: Recruitment Success in the Asia-Pacific

The Study George Clinical (GC) is collaborating with a global, research-based biopharmaceutical company to evaluate the effect of a new chemical entity in subjects with type 2 diabetes and nephropathy. George Clinical services GC is responsible for project management (PM) and monitoring throughout the Asia-Pacific. Other regions were managed by a separate contract research organization […]

Read More

January 23rd, 2017

Oncology: Recruitment Success in China

The Study George Clinical (GC) collaborated with a mid-sized global pharmaceutical company to conduct a randomized trial comparing pain relief medication for patients with moderate to severe chronic cancer pain. George Clinical services GC was responsible for project management (PM) and monitoring across 26 sites in China. Study sites were located in Beijing, Changchun, Dalian, […]

Read More

January 23rd, 2017

Oncology: Multiple services; one provider

With the support of George Clinical (GC), The George Institute (TGI) for Global Health conducted a longitudinal cohort study of approximately 9,500 hospital patients with a first time diagnosis of cancer. The study was conducted across eight countries, namely: Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand and Vietnam. The aim of the study was to […]

Read More

June 22nd, 2016

George Clinical Awarded Contract for Clinical Trial Management Services on Rotavirus Vaccine

George Clinical has recently been awarded the contract for full service clinical trial management services for a clinical study that seeks to improve the formulation further and also the current administration challenges for a rotavirus vaccine. The vaccine was recently launched by Indian Prime Minister Narendra Modi and developed by a Hyderabad based healthcare organization […]

Read More

June 21st, 2016

Outstanding metrics achieved for a Phase III diabetes study in China

The World Health Organization estimates that 347 million people worldwide have diabetes, and that number is expected to continue increasing as more people move to urban cities and the population ages. Low and middle-income countries, like China and India, have been hit hardest with this disease and other NCDs. In 2010, the total number of […]

Read More

June 21st, 2016

New treatment for the most serious form of stroke

Intracerebral hemorrhage is the most serious form of stroke with high rates of mortality and a low chance of recovery to functional independence. In Asia-Pacific, it affects more than one million people annually, kills one third of them and leaves most survivors with disability. For reasons yet unknown, intracerebral hemorrhage is also more prevalent in […]

Read More

June 21st, 2016

Developing clinical trials to meet the demands of 21st century diseases

Diseases that dominate the 21st century need a 21st century approach in the way we design and conduct clinical trials. To meet this need, George Clinical is primarily focused on large-scale studies with high-impact outcomes, particularly where smaller pre-registration trials need to be expanded to larger populations. George Clinical has been managing clinical trials in […]

Read More

June 21st, 2016

COPD and its co-morbidities

COPD is one of the world’s leading cause of death with prevalence ranging from 6% to 19% globally. This disease is particularly relevant for us in Asia-Pacific as risk factors such as smoking, biomass fuels, TB and air pollution are more prevalent than other regions. For example COPD prevalence in Chinese males is estimated to […]

Read More

June 21st, 2016

Intensive blood pressure lowering reduces heart attacks

One quarter of the world’s adult population suffers from hypertension, and although it has no obvious symptoms, it can lead to heart attacks, stroke, kidney failure and blindness. Despite this, there has been great uncertainty as to how intensively blood pressure should be lowered to obtain maximal benefit and minimize risks. Researchers from Australia, China, […]

Read More

June 21st, 2016

Benefits of DPPIV-inhibitors still uncertain

The recent SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials recently reported the effects of the DPPIV inhibitor class of glucose lowering agents in people with diabetes. As required by the US FDA, both drugs were found not to increase cardiovascular risk, allowing the agents to be registered for use in that country. Good news, it would […]

Read More

June 21st, 2016

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network